Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$11.0 million.

  • Aclaris Therapeutics' Free Cash Flow fell 149.80% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.0 million, marking a year-over-year decrease of 132.97%. This contributed to the annual value of -$20.2 million for FY2024, which is 74.64% up from last year.
  • Aclaris Therapeutics' Free Cash Flow amounted to -$11.0 million in Q3 2025, which was down 9.40% from -$10.0 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Free Cash Flow peaked at $22.0 million during Q3 2024, and registered a low of -$26.9 million during Q1 2023.
  • Its 3-year average for Free Cash Flow is -$12.2 million, with a median of -$12.3 million in 2024.
  • Per our database at Business Quant, Aclaris Therapeutics' Free Cash Flow slumped by 209.29% in 2023 and then spiked by 189.28% in 2024.
  • Aclaris Therapeutics' Free Cash Flow (Quarterly) stood at -$17.3 million in 2021, then decreased by 11.26% to -$19.2 million in 2022, then skyrocketed by 62.53% to -$7.2 million in 2023, then decreased by 24.10% to -$8.9 million in 2024, then crashed by 149.80% to -$11.0 million in 2025.
  • Its last three reported values are -$11.0 million in Q3 2025, -$10.0 million for Q2 2025, and -$13.1 million during Q1 2025.